A cycloruthenated complex, ruthenium (II) Z (RuZ) overcomes in vitro and in vivo multidrug resistance in cancer cells: A pivotal breakthrough.

Abstract

Multidrug resistance (MDR) is one of the major obstacles that attenuates or abrogates the efficacy of the treatment of cancer.[1] Previously, numerous studies have reported that certain metallo-complexed anticancer drugs, such as platinum (II)based compounds, are efficacious in treating specific types of cancer.[2] However, these compounds are not efficacious in MDR cancers. Consequently, there is a need for the synthesis and development of safe and efficacious metal-complexed anticancer drugs.